MREO
MREO clinical trials: Mereo BioPharma Group plc
Every trial on ClinicalTrials.gov where Mereo BioPharma Group plc is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 23
- Trials linked
- 12
- As lead sponsor
- 11
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
MREO on the catalyst calendar · MREO registry changes
- Primary completion Oct 30, 2023ActualPhase 1/Phase 2NCT04761198A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic TumorsMereo BioPharma · Solid Tumor, AdultCompletedMREOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 8, 2018ActualPhase 2NCT02908074A 6 Month Safety Extension Study of MBGS205Mereo BioPharma · Hypogonadotropic HypogonadismCompletedMREOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2013ActualPhase 2NCT01332097Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an ExacerbationMereo BioPharma · Chronic Obstructive Pulmonary DiseaseCompletedMREOLeadNVSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 15, 2018ActualPhase 2NCT02730169Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic HypogonadismMereo BioPharma · Hypogonadotropic HypogonadismCompletedMREOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2, 2022ActualPhase 2NCT03636347A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.Mereo BioPharma · Alpha 1-Antitrypsin DeficiencyCompletedMREOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 8, 2017ActualPhase 2NCT02700919Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary DiseaseMereo BioPharma · Pulmonary Disease, Chronic ObstructiveCompletedMREOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2013ActualPhase 2NCT01336959Safety & Efficacy of BCT197 in Patients Undergoing Cardiac SurgeryMereo BioPharma · Acute Kidney InjuryTerminatedMREOLeadNVSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2011ActualPhase 2NCT01116440A Safety & Efficacy Study of BGS649 in Women With Refractory EndometriosisMereo BioPharma · Pelvic Pain Associated With Refractory EndometriosisTerminatedMREOLeadNVSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2012ActualPhase 2NCT01200862Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal MenMereo BioPharma · Obese Hypogonadotropic HypogonadismTerminatedMREOLeadNVSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2011ActualPhase 2NCT01190475BGS649 Monotherapy in Moderate to Severe Endometriosis PatientsMereo BioPharma · EndometriosisCompletedMREOLeadNVSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 3, 2018ActualPhase 1NCT03498170The Effect of Itraconazole on BCT197 Exposure in Healthy Male ParticipantsMereo BioPharma · InteractionCompletedMREOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2016ActualPhase 1NCT02926326The Effect of Azithromycin on BCT197 Exposure in Healthy Male VolunteersMereo BioPharma · InteractionCompletedMREOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 20, 2025ActualPhase 2/Phase 3NCT05125809Setrusumab vs Placebo for Osteogenesis ImperfectaUltragenyx Pharmaceutical Inc · Osteogenesis ImperfectaActive, not recruitingRARELeadMREOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2025ActualPhase 2NCT05715216EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With...M.D. Anderson Cancer Center · Ovarian CancerActive, not recruitingMREOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 7, 2022ActualPhase 2NCT05312697Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis ImperfectaUltragenyx Pharmaceutical Inc · Osteogenesis ImperfectaTerminatedRARELeadMREOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2023ActualPhase 2NCT03679598Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin DeficiencyUniversity of Alabama at Birmingham · Alpha-1 Antitrypsin Deficiency (AATD)CompletedMREOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 1, 2018Sponsor estimatePhase 2NCT03216486An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis ImperfectaUltragenyx Pharmaceutical Inc · Osteogenesis ImperfectaWithdrawnRARELeadMREOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 1, 2019ActualPhase 2NCT03118570A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804Ultragenyx Pharmaceutical Inc · Osteogenesis Imperfecta, Type ICompletedRARELeadMREOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 29, 2021ActualPhase 1/Phase 2NCT04539795COVID-19 Study of Safety and Tolerability of AlvelestatUniversity of Alabama at Birmingham · Covid19CompletedMREOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2014Sponsor estimatePhase 2NCT01806610Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney DiseaseUltragenyx Pharmaceutical Inc · Chronic-kidney Disease Stage 5D on Stable Hemodialysis
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2012ActualPhase 2NCT01406977Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP)Ultragenyx Pharmaceutical Inc · Hypophosphatasia
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2013ActualPhase 2NCT01406548Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral DensityUltragenyx Pharmaceutical Inc · Osteopenia
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2022Sponsor estimatePhase 1/Phase 2NCT03986086MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell TransplantationNelson Chao · Hematologic MalignancyWithdrawnMREOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 23 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner